Vaxcyte (PCVX) said Wednesday its ongoing phase 2 study assessing VAX-31 for the prevention of invasive pneumococcal disease in infants is advancing to its second and final stage.

The company said participants who received VAX-31 in the first stage will continue the standard dosing regimen as part of the second stage.

Vaxcyte said it expects to release topline data from the study's primary three-dose immunization series in the middle of next year, followed by topline data from the booster dose about nine months later.

In infants, the VAX-31 was designed to cover about 94% of invasive pneumococcal disease and roughly 93% of acute otitis media caused by streptococcus pneumoniae in children under five years old in the United States.

Shares of Vaxcyte were up nearly 3% in recent trading.

Price: 88.88, Change: +2.37, Percent Change: +2.73